facebook linkedin twitter

Johnson & Johnson 1-dose Shot Prevents COVID-19, But Less Than Some Others

January 29, 2021by Lauran Neergaard and Linda A. Johnson, Associated Press
Johnson & Johnson 1-dose Shot Prevents COVID-19, But Less Than Some Others
This Sept. 2020 photo provided by Johnson & Johnson shows the investigational Janssen COVID-19 vaccine. Johnson & Johnson's long-awaited COVID-19 vaccine appears to protect against symptomatic illness with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. Johnson & Johnson said Friday, Jan. 29, 2021 that in the U.S. and seven other countries, the first single-shot vaccine appears 66% effective overall at preventing moderate to severe COVID-19. It was more protective against severe symptoms, 85%. (Cheryl Gerber/Johnson & Johnson via AP)

Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses.

J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms.

There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus.

“Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press.

With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies and avoid the logistics nightmare of getting people to return for boosters.

But with some other competing vaccines shown to be 95% effective after two doses, at question is whether somewhat less protection is an acceptable tradeoff to get more shots in arms quickly.

The company said within a week, it will file an application for emergency use in the U.S., and then abroad. It expects to supply 100 million doses to the U.S. by June, and expects to have some ready to ship as soon as authorities give the green light.

These are preliminary findings from a study of 44,000 volunteers that isn’t completed yet. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.

After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Mammen said. When the vaccinated did become infected, they had a milder illness.

Defeating the scourge that has killed more than 2 million people worldwide will require vaccinating billions, and the shots being rolled out in different countries so far all require two doses a few weeks apart for full protection. Early data is mixed on exactly how well all the different kinds work, but shots made by Pfizer and Moderna appear to be about 95% protective after the second dose.

But amid shortages, some countries have advised delaying the second dose of certain vaccines with little data on how that would affect protection.

All COVID-19 vaccines train the body to recognize the new coronavirus, usually by spotting the spikey protein that coats it. But they’re made in very different ways.

J&J’s shot uses a cold virus like a Trojan horse to carry the spike gene into the body, where cells make harmless copies of the protein to prime the immune system in case the real virus comes along.

Rival AstraZeneca makes a similar cold virus vaccine that requires two doses. Both the AstraZeneca and J&J vaccines can be stored in a refrigerator, making them easier to ship and to use in developing countries than the frozen kind made by Pfizer and Moderna.

It’s not clear exactly how well the AstraZeneca version, being used in Britain and several other countries, works. Tests in Britain, South Africa and Brazil suggested two doses are about 70% effective although there are questions about how much protection older adults get. An ongoing U.S. study may provide more information.

J&J said its vaccine works consistently in a broad range of people: A third of participants were over age 60, and more than 40% had other illnesses putting them at risk of severe COVID-19, including obesity, diabetes and HIV.

J&J said the vaccine is safe, with reactions similar to other COVID-19 shots such as fever that occur when the immune system is revved up.

While it released few details, the company said there were no serious allergic reactions. But occasionally other COVID-19 vaccines trigger such reactions, which can be reversed if promptly treated – and authorities have warned people to be on the lookout regardless of which type of vaccine is used.

J&J had hedged its bets with a study of a two-dose version of its vaccine, which is still underway.

Friday’s interim results come on the heels of another vaccine in final testing. Novavax reported this week that its vaccine appears 89% effective in a U.K. study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in Britain and South Africa. A larger study in the U.S. and Mexico is still enrolling volunteers.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

A+
a-

In The News

Health

Voting

Health

January 24, 2022
by Tom Ramstack
Sarah Palin Diagnosed With COVID Before New York Times Lawsuit Trial

NEW YORK — Former vice-presidential candidate Sarah Palin was diagnosed with COVID-19 this weekend, which delayed her defamation lawsuit against... Read More

NEW YORK — Former vice-presidential candidate Sarah Palin was diagnosed with COVID-19 this weekend, which delayed her defamation lawsuit against The New York Times that was scheduled for a trial beginning Monday. Palin reported her illness to Judge Jed Rakoff of the U.S. District Court in... Read More

January 24, 2022
by Reece Nations
Political Polarization Impeded Public Support for COVID-19 Response

SAN ANTONIO — Public sentiment regarding COVID-19 mitigation strategies was undermined by polarization from political actors around the globe, according... Read More

SAN ANTONIO — Public sentiment regarding COVID-19 mitigation strategies was undermined by polarization from political actors around the globe, according to new research published in the Proceedings of the National Academy of Sciences. Researchers from around the world contributed to the study which examined the effects... Read More

January 24, 2022
by Tom Ramstack
FBI Cracks Down on Organizations Accused of Cashing In on the Pandemic

WASHINGTON —  The FBI is investigating an Illinois company that has received $124 million from the federal government for COVID-19... Read More

WASHINGTON —  The FBI is investigating an Illinois company that has received $124 million from the federal government for COVID-19 testing after reports the owners were using part of the money for lavish lifestyles. FBI agents raided the headquarters in Rolling Meadows, Illinois, Saturday. It opened... Read More

New Conservative Target: Race as Factor in COVID Treatment

MADISON, Wis. (AP) — Some conservatives are taking aim at policies that allow doctors to consider race as a risk... Read More

MADISON, Wis. (AP) — Some conservatives are taking aim at policies that allow doctors to consider race as a risk factor when allocating scarce COVID-19 treatments, saying the protocols discriminate against white people. The wave of infections brought on by the omicron variant and a shortage of... Read More

China Tests 2M in Beijing, Lifts COVID Lockdown in Xi’an

BEIJING (AP) — A cluster of COVID-19 cases in Beijing has prompted authorities to test millions and impose new measures... Read More

BEIJING (AP) — A cluster of COVID-19 cases in Beijing has prompted authorities to test millions and impose new measures two weeks ahead of the opening of the Winter Olympics, even as the city of Xi'an in north-central China lifted on Monday a monthlong lockdown that... Read More

US Jobless Claims Rise to 286,000, Highest Since October

WASHINGTON (AP) — The number of Americans applying for unemployment benefits rose to the highest level in three months as... Read More

WASHINGTON (AP) — The number of Americans applying for unemployment benefits rose to the highest level in three months as the fast-spreading omicron variant continued to disrupt the job market. Jobless claims rose for the third straight week — by 55,000 to 286,000, highest since mid-October,... Read More

News From The Well
scroll top